Gout.

Gout / blood Gout Suppressants / pharmacology Humans Patient Care Management / methods Risk Reduction Behavior Uric Acid / metabolism
Gout Gout suppressants Preventive target Serum urate Therapeutic target Therapy

Journal

Rheumatic diseases clinics of North America
ISSN: 1558-3163
Titre abrégé: Rheum Dis Clin North Am
Pays: United States
ID NLM: 8708093

Informations de publication

Date de publication:
11 2019
Historique:
entrez: 1 10 2019
pubmed: 1 10 2019
medline: 1 5 2020
Statut: ppublish

Résumé

The treat to target strategy looks attractive for management of gout because it removes the causal mechanism inducing formation, growth, and aggregation of urate crystals. Further reduction of serum urate (sUA) levels below the threshold may dissolve crystals more rapidly. It is generally agreed that sUA less than 6 mg/dL is acceptable as a therapeutic and long-term preventive target, with <5 mg/dL for the most severe cases. The challenges that this approach in gout is facing include whether proposed targets are the best for desired outcomes, whether they fit patient-related outcomes, and whether they adequately balance effectiveness and safety.

Identifiants

DOI: 10.1016/j.rdc.2019.08.001 PMID: 31564298
pubmed: 31564298
pii: S0889-857X(19)30063-8
doi: 10.1016/j.rdc.2019.08.001
pii:
doi:

Substances chimiques

Gout Suppressants 0
Uric Acid 268B43MJ25

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

583-591

Informations de copyright

Copyright © 2019 Elsevier Inc. All rights reserved.

Auteurs

Fernando Perez-Ruiz (F)

Department of Medicine, Medicine and Nursery School, University of the Basque Country, University Building, 2nd Floor, Pza Cruces sn, Baracaldo 48903, Spain. Electronic address: fernando.perezruiz@osakidetza.net.

Nicola Dalbeth (N)

Department of Medicine, Bone and Joint Research Group, Faculty of Medical and Health Sciences, University of Auckland, Room 502-201D, 85 Park Road, Grafton, Auckland 1023, New Zealand; Department of Rheumatology, Auckland District Health Board, Auckland, New Zealand.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Maladies métaboliques et nutritionnelles › Maladies métaboliques › Erreurs innées du métabolisme › Erreurs innées du métabolisme de la purine et de la pyrimidine › Goutte › Gout.
questionsmedicales.fr › Actions chimiques et utilisations › Actions pharmacologiques › Utilisations thérapeutiques › Antirhumatismaux › Antigoutteux › Gout.
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Gout.
questionsmedicales.fr › Administration des services de santé › Gestion des soins aux patients › Gout.
questionsmedicales.fr › Comportement et mécanismes comportementaux › Comportement › Comportement de réduction des risques › Gout.
questionsmedicales.fr › Composés hétérocycliques › Composés hétérocycliques à cycles fusionnés › Composés hétérobicycliques › Purines › Purinones › Xanthines › Acide urique › Gout.